Surrey Heartlands

Joint Formulary & PAD

Vacuum erection devices - Erectile dysfunction combination therapy

You are here : Home > Formulary Search > Vacuum erection devices - Erectile dysfunction combination therapy

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Non Formulary
Formulations :
  • Not Specified
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
NFD1
Restrictions / Comments :

Documentation

Policy Statement
Erectile dysfunction oral and non oral combination treatments - Policy statement PCN 24-2012 - Jun 2
Evidence Review
Erectile dysfunction combination treatments evidence review June 2012

PAD Profile

ChemicalSubstance :
Vacuum erection devices
Indication :
Erectile dysfunction combination therapy
Group Name :
Keywords :
ED, impotence
Brand Names Include :
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
2

Other Indications

Below are listed other indications that Vacuum erection devices is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Erectile dysfunction combination therapy.

Committee Recommendations (2)

03 Jun 20 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

At the Surrey and North-West Sussex Area Prescribing Committee (APC) held in June 2020, it was decided that all BLACK status drugs would have their review dates extended for 5 years without the need for a review.

If a clinician or provider wishes to change the traffic light status of any BLACK drug then they will need to submit a paper for change as per usual APC process.

27 Jun 12 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

 

Use of both oral and non-oral combination treatments for erectile dysfunction in patients who had not responded or had a sub-optimal response to monotherapy was considered.The network members concurred that based on the limited available evidence, noting the feedback from clinicians, that combination treatments should not be supported and a BLACK status should be given on the PAD.Please see policy statement from June 2012